Trial Profile
Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Methotrexate; Methylprednisolone; Methylprednisolone
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- 26 Feb 2024 Planned End Date changed from 1 Mar 2024 to 1 Dec 2024.
- 17 Oct 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2024.
- 17 Sep 2021 Planned End Date changed from 1 Dec 2019 to 1 Mar 2022.